SCHEMBL25075141

SCHEMBL25075141

CC[C@@H]1CCN(CCCC(=O)N2CCC(C(C)C)CC2)C1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 8/20 0.44
GNAO1 P09471 8/20 0.44
GNAI1 P63096 8/20 0.44
NPC1 O15118 1/20 0.42
PDCD1 Q15116 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
DPP8 Q6V1X1 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
ITGB3 P05106 2/20 0.36
ITGA2B P08514 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HSD11B1 P28845 1/20 0.35
BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25075451 0.92 GNAI3 (0.46) GNAI3GNAO1GNAI1NPC1PDCD1
SCHEMBL26494158 0.90 NPC1 (0.43) GNAI3GNAO1GNAI1NPC1PDCD1
SCHEMBL26494363 0.90 NPC1 (0.43) GNAI3GNAO1GNAI1NPC1PDCD1
SCHEMBL25075138 0.90 NPC1 (0.43) GNAI3GNAO1GNAI1NPC1PDCD1
SCHEMBL26494350 0.89 NPC1 (0.46) GNAI3GNAO1GNAI1NPC1PDCD1
SCHEMBL26494145 0.89 NPC1 (0.46) GNAI3GNAO1GNAI1NPC1PDCD1
SCHEMBL25075318 0.89 NPC1 (0.46) GNAI3GNAO1GNAI1NPC1PDCD1
SCHEMBL25075204 0.87 NPC1 (0.50) GNAI3GNAO1GNAI1NPC1PDCD1
SCHEMBL26499180 0.86 GNAI3 (0.40) GNAI3GNAO1GNAI1NPC1PDCD1
SCHEMBL26494176 0.85 NPC1 (0.47) GNAI3GNAO1GNAI1NPC1PDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed
WO-2023023537-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. (US) 2023-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN GNAI3 1728/4885GNAO1 3018/4885GNAI1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.